| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
EDIT Overview
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
Editas Medicine Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$37.82 |
| 52 Week High | US$27.12 |
| 52 Week Low | US$99.95 |
| Beta | 2.07 |
| 1 Month Change | -36.02% |
| 3 Month Change | -7.40% |
| 1 Year Change | 15.45% |
| 3 Year Change | 45.57% |
| 5 Year Change | 188.70% |
| Change since IPO | 107.80% |
Recent News & Updates
Is Editas Medicine (NASDAQ:EDIT) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Editas: Gene Therapy Specialist Leading The Way In Eye Disease
Editas is one of a triumvirate of gene-therapy companies pioneering CRISPR/Cas9 gene-editing technology - the others being CRISPR Therapeutics and Intellia. Intellia's recent success in an in-human trial of patients with transthyretin (ATTR) amyloidosis has created a bull market for these companies. Editas has its own major data readout upcoming in the eye condition Leber Congenital Amaurosis 10 - which could be a major upside catalyst for the share price. At half the market cap of CRISPR and Intellia, Editas is worth considering as an addition to a balanced portfolio. The company has a relatively new management team, >$600m in cash, and a deep, albeit early stage pipeline.
Shareholder Returns
| EDIT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.5% | 0.5% | 1.7% |
| 1Y | 15.4% | 16.1% | 30.3% |
Return vs Industry: EDIT underperformed the US Biotechs industry which returned 17.1% over the past year.
Return vs Market: EDIT underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| EDIT volatility | |
|---|---|
| EDIT Beta | 2.07 |
| Industry Beta | 0.98 |
| Market Beta | 1 |
Stable Share Price: EDIT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: EDIT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 235 | Jim Mullen | https://www.editasmedicine.com |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood.
Editas Medicine Fundamentals Summary
| EDIT fundamental statistics | |
|---|---|
| Market Cap | US$2.58b |
| Earnings (TTM) | -US$166.66m |
| Revenue (TTM) | US$81.14m |
31.8x
P/S Ratio-15.5x
P/E RatioIs EDIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EDIT income statement (TTM) | |
|---|---|
| Revenue | US$81.14m |
| Cost of Revenue | US$171.11m |
| Gross Profit | -US$89.97m |
| Expenses | US$76.69m |
| Earnings | -US$166.66m |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.45 |
| Gross Margin | -110.89% |
| Net Profit Margin | -205.41% |
| Debt/Equity Ratio | 0% |
How did EDIT perform over the long term?
See historical performance and comparisonValuation
Is Editas Medicine undervalued compared to its fair value and its price relative to the market?
4.2x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EDIT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EDIT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EDIT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: EDIT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EDIT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EDIT is overvalued based on its PB Ratio (4.2x) compared to the US Biotechs industry average (2.9x).
Future Growth
How is Editas Medicine forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
16.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EDIT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EDIT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EDIT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EDIT's revenue (60.5% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: EDIT's revenue (60.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EDIT is forecast to be unprofitable in 3 years.
Past Performance
How has Editas Medicine performed over the past 5 years?
-8.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EDIT is currently unprofitable.
Growing Profit Margin: EDIT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EDIT is unprofitable, and losses have increased over the past 5 years at a rate of 8.3% per year.
Accelerating Growth: Unable to compare EDIT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EDIT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: EDIT has a negative Return on Equity (-27.17%), as it is currently unprofitable.
Financial Health
How is Editas Medicine's financial position?
Financial Position Analysis
Short Term Liabilities: EDIT's short term assets ($616.3M) exceed its short term liabilities ($66.0M).
Long Term Liabilities: EDIT's short term assets ($616.3M) exceed its long term liabilities ($76.5M).
Debt to Equity History and Analysis
Debt Level: EDIT is debt free.
Reducing Debt: EDIT had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EDIT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: EDIT has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 40.4% each year.
Dividend
What is Editas Medicine current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EDIT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EDIT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EDIT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EDIT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EDIT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.8yrs
Average management tenure
CEO
Jim Mullen (62 yo)
0.67
Tenure
US$304,438
Compensation
Mr. James C. Mullen, also known as Jim, serves as Chief Executive Officer and President of Editas Medicine, Inc. since February 15, 2021. He serves as a Member of Strategic Advisory Board at Longwood Fund....
Leadership Team
Experienced Management: EDIT's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
Experienced Board: EDIT's board of directors are considered experienced (3.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: EDIT insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.4%.
Top Shareholders
Company Information
Editas Medicine, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Editas Medicine, Inc.
- Ticker: EDIT
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.578b
- Shares outstanding: 68.15m
- Website: https://www.editasmedicine.com
Number of Employees
Location
- Editas Medicine, Inc.
- 11 Hurley Street
- Cambridge
- Massachusetts
- 2141
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/10/22 23:08 |
| End of Day Share Price | 2021/10/22 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.